
Research ArticleRandomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
Keywords: HCV; hepatitis C virus; PegIFNα; peginterferon alfa; RBV; ribavirin; DAA; direct-acting antiviral; BID; twice daily; SVR24; sustained virologic response 24 weeks posttreatment; PDR; protocol-defined response; LLOQ; lower limit of quantification; EVR; ea